Company intelligence / Profile preview

Boehringer Ingelheim Vetmedica

Ingelheim am Rhein, Germany

Ownership: Private
Employees: ~10000
Development stage: Other

Overview

Commercial-stage animal health division with established products including vaccines, parasite controls, antibiotics, and therapeutics for pets, livestock, horses, swine, and poultry.

Therapeutic areas: CardiovascularEndocrinologyNeurologyInfectious DiseasesPulmonologyGastroenterology
Modalities: Small moleculeVaccineBiologic
Industry: Veterinary

Partnerships

Pfizer (historical acquisition)Merial (acquired in 2017)Elanco (asset sale)

Beyond the preview

Go deeper on Boehringer Ingelheim Vetmedica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boehringer Ingelheim Vetmedica.

Explore the full profile